Skip to main content

Incyte Corp(INCY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low66.56
Day High67.91
Open:66.84
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

Incyte: Top 25 Undervalued Nasdaq Composite Index Stocks (INCY)
The Globe and Mail - Mon Sep 5, 9:09AM CDT
The Globe and Mail
Mon Sep 5, 9:09AM CDT
Incyte is now ranked among the top 25 undervalued stocks included in the Nasdaq Composite Index. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a...
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
Business Wire - Fri Aug 26, 9:00AM CDT
Business Wire
Fri Aug 26, 9:00AM CDT
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory...
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
Business Wire - Wed Aug 24, 7:00AM CDT
Business Wire
Wed Aug 24, 7:00AM CDT
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan...

Latest Articles

Lilly lays out faster time frame for FDA drug resubmission
Wal-Mart Stores, Pandora rise; Ascena Retail, Alibaba fall
IBM and Revlon slide while VWR and Herbalife jump
Reynolds American, IHS, Yahoo and Incyte are big market movers